Wealth Dimensions Group Ltd. Sells 181 Shares of AstraZeneca PLC (NASDAQ:AZN)

Wealth Dimensions Group Ltd. cut its position in AstraZeneca PLC (NASDAQ:AZN) by 3.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,395 shares of the company’s stock after selling 181 shares during the period. Wealth Dimensions Group Ltd.’s holdings in AstraZeneca were worth $420,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Swedbank AB bought a new stake in AstraZeneca in the first quarter worth about $186,127,000. Manning & Napier Advisors LLC bought a new stake in AstraZeneca during the 2nd quarter worth approximately $188,476,000. Hsbc Holdings PLC lifted its stake in AstraZeneca by 750.3% in the 2nd quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock worth $100,523,000 after purchasing an additional 1,132,362 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in AstraZeneca by 65.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock valued at $187,934,000 after purchasing an additional 950,000 shares during the period. Finally, AGF Management Ltd. grew its position in shares of AstraZeneca by 63.5% during the 2nd quarter. AGF Management Ltd. now owns 1,303,559 shares of the company’s stock valued at $101,665,000 after purchasing an additional 506,465 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

NASDAQ:AZN opened at $65.63 on Friday. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The business has a 50 day moving average of $73.44 and a 200 day moving average of $77.80. The company has a market capitalization of $203.49 billion, a price-to-earnings ratio of 31.40, a PEG ratio of 1.20 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same period in the prior year, the business posted $0.87 earnings per share. The company’s revenue was up 18.0% on a year-over-year basis. On average, sell-side analysts predict that AstraZeneca PLC will post 4.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday. TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.